Recent 8-K filings for ODTX
Highest-materiality recent filing
Odyssey OD-001 Phase 2a UC induction: 27% clinical remission at 20mg BID; primary endpoint met
- Primary endpoint met: mean 2.4-point reduction in modified Mayo score at Week 12 across 56 efficacy-evaluable patients (p<0.001).
- 20 mg BID (n=41): clinical remission 27%, clinical response 61%, symptomatic remission 49%; 10 mg BID (n=15): 20%, 40%, 27%.
-
Odyssey OD-001 Phase 2a UC induction: 27% clinical remission at 20mg BID; primary endpoint met
Primary endpoint met: mean 2.4-point reduction in modified Mayo score at Week 12 across 56 efficacy-evaluable patients (p<0.001).
-
Odyssey Therapeutics posts corporate presentation; no financial details in 8-K
Odyssey Therapeutics posted a corporate presentation on its investor relations website on September 8, 2026.
-
Odyssey Therapeutics Q2 2026 net loss $52.8M; cash $433.1M; OD-001 data at UEG Week
Net loss $52.8M for Q2 2026 vs $41.2M in Q2 2025; adjusted net loss (non-GAAP) $38.4M.
-
Odyssey Therapeutics posts June 2026 corporate presentation on website
Presentation furnished as Exhibit 99.1; no specific financial or clinical updates provided in filing text.
-
Odyssey Therapeutics Q1 net loss $38.3M; pro-forma cash $464M; positive OD-001 data
Cash and securities $175.7M at Mar 31, 2026; pro-forma cash $464.4M after IPO net proceeds of $288.7M.
-
Private placement of 1,388,889 shares of common stock at $18.00 per share for total proceeds of $25,000,002.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.57 · Most common event other_material